Provides certificate and degree programs in healthcare-related fields. Offers training in areas such as ultrasound technology, vocational nursing, and medical assisting. Now — the numbers.
This is an established company with proven profits.
No real growth (3% a year).
The market pays 17× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 48% of them.
Analysts' average target sits 43% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades 29% below its peak. The market has trimmed its expectations for the company.
There is $20.3M in the vault; even if every debt were paid off, $2.6M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 4 years, sales grew only 3% a year on average — the report card’s higher growth grade leans on profit power instead.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 42/100. For a turnaround signal, the stock first needs to close the gap with the market.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 48/100.
On our five-subject report card, LGCY sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: LGCY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Analysts’ average target sits above today’s price, yet the valuation grade (48/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.